IL-33, ST2, and ILC Pathways
IL-33, ST2, and ILC Pathways is a research topic within Immunology. Science Explorer counts 17k research works in it since 1954. 25.8% of them reached the world's top 10% most cited for their field and year.
This cluster of papers explores the role of innate lymphoid cells, particularly their interaction with IL-33, in regulating type 2 immunity, tissue homeostasis, mucosal immunity, allergic inflammation, and the interplay with the adaptive immune system. It also delves into their involvement in various inflammatory diseases and their influence on regulatory T cells.
- Innate Lymphoid Cells
- IL-33
- Type 2 Immunity
- Tissue Homeostasis
- Interleukin-1 Family
- Mucosal Immunity
- Allergic Inflammation
- Regulatory T Cells
- Adaptive Immune System
- Inflammatory Diseases
- Research works
- 17k fractional, since 1954
- In the world top 10%
- 4.3k per year above
- Top-10% rate
- 25.8% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +33% the tick is no change
Which countries lead IL-33, ST2, and ILC Pathways research?
By volume, China and the United States publish the most (1.1k and 923 works in 2022–2025).
By volume, 2022–2025
- 1 China 1.1k works
- 2 United States 923 works
- 3 Japan 192 works
- 4 Germany 182 works
- 5 United Kingdom 171 works
- 6 Italy 133 works
- 7 France 113 works
- 8 South Korea 111 works
- 9 Canada 94 works
- 10 Spain 91 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead IL-33, ST2, and ILC Pathways research?
By volume in 2022–2025, Harvard University publishes the most IL-33, ST2, and ILC Pathways research, followed by Washington University in St. Louis and Nanjing Medical University.
By volume, 2022–2025
- 1 Harvard UniversityUnited States 18 works
- 2 Washington University in St. LouisUnited States 18 works
- 3 Nanjing Medical UniversityChina 18 works
- 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 17 works
- 5 University of PittsburghUnited States 17 works
- 6 Sun Yat-sen UniversityChina 16 works
- 7 InsermFrance 15 works
- 8 Imperial College LondonUnited Kingdom 15 works
- 9 Shanghai Jiao Tong UniversityChina 15 works
- 10 Central South UniversityChina 15 works
Who are the leading researchers in IL-33, ST2, and ILC Pathways?
The most-cited researchers publishing on IL-33, ST2, and ILC Pathways include Shizuo Akira, Veikko Salomaa and Peter R. Galle.
- 1 Shizuo Akira Japan 3.6k citations
- 2 Veikko Salomaa Finland 3.3k citations
- 3 Peter R. Galle Germany 3.3k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is IL-33, ST2, and ILC Pathways research done?
The largest centres of IL-33, ST2, and ILC Pathways research in 2022–2025 are Beijing (China), Shanghai (China), Guangzhou (China) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Denver and Bethesda.
Largest cities, 2022–2025
Where it is the local speciality
- DenverUS · 20.2 works7.9×
- BethesdaUS · 30.0 works6.2×
Location quotient: how much more of its research is in IL-33, ST2, and ILC Pathways than the world average.
Where is the best place to study IL-33, ST2, and ILC Pathways?
Among universities, judged by research, Nanjing Medical University, Washington University in St. Louis and Harvard University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Nanjing Medical UniversityChina | 66.3 | 24.9% | 9.1× | 18 | +110.5% |
| 2 | Washington University in St. LouisUnited States | 64.7 | 30.9% | 6.6× | 18 | +105.1% |
| 3 | Harvard UniversityUnited States | 63.1 | 42.8% | 3.7× | 18 | +16.0% |
| 4 | Guangzhou Medical UniversityChina | 60.8 | 21.3% | 10.7× | 11 | +185.5% |
| 5 | Southern Medical UniversityChina | 60.7 | 34.6% | 8.8× | 12 | +69.8% |
| 6 | University of Southern CaliforniaUnited States | 58.0 | 37.9% | 4.0× | 12 | +198.6% |
| 7 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 57.1 | 28.6% | 4.6× | 17 | +129.1% |
| 8 | China Medical UniversityChina | 55.5 | 21.5% | 9.8× | 12 | +103.1% |
| 9 | Cornell UniversityUnited States | 54.3 | 38.6% | 2.7× | 11 | +234.4% |
| 10 | University of Colorado DenverUnited States | 53.4 | 23.6% | 9.7× | 12 | +36.1% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is IL-33, ST2, and ILC Pathways research growing?
Output in 2018–2022 was 33% higher than in 2013–2017, peaking in 2022. The fastest-growing topics are IL-33, ST2, and ILC Pathways.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.